Holen Sie sich die Stockscreener-App
28.79
3.40%
-1.03
Schlusskurs vom Vortag:
$29.82
Offen:
$30.05
24-Stunden-Volumen:
802.49K
Relative Volume:
1.01
Marktkapitalisierung:
$3.31B
Einnahmen:
$14.09M
Nettoeinkommen (Verlust:
$-176.94M
KGV:
-13.39
EPS:
-2.15
Netto-Cashflow:
$-141.24M
1W Leistung:
-3.53%
1M Leistung:
-16.82%
6M Leistung:
+19.08%
1J Leistung:
+22.16%
1-Tages-Spanne:
$28.76
$30.74
1-Wochen-Bereich:
$28.76
$31.71
52-Wochen-Spanne:
$14.06
$42.00
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
Firmenname
Newamsterdam Pharma Company Nv
Sektor
Branche
Telefon
35 206 2971
Adresse
GOOIMEER 2-35, NARRDEN
Compare NAMS vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
28.76 | 3.43B | 14.09M | -176.94M | -141.24M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.91 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
743.55 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
702.16 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.97 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
283.89 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-20 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-08-25 | Eingeleitet | Wells Fargo | Overweight |
| 2025-07-17 | Eingeleitet | Goldman | Neutral |
| 2025-06-17 | Eingeleitet | Citigroup | Buy |
| 2025-06-10 | Eingeleitet | Stifel | Buy |
| 2025-06-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-15 | Eingeleitet | TD Cowen | Buy |
| 2024-03-14 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-01-18 | Eingeleitet | Guggenheim | Buy |
| 2024-01-16 | Eingeleitet | Piper Sandler | Overweight |
| 2023-10-30 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Newamsterdam Pharma Company Nv Aktie (NAMS) Neueste Nachrichten
Insider Sell: Louis Lange Sells 44,619 Shares of NewAmsterdam Ph - GuruFocus
NewAmsterdam Pharma Company N.V. $NAMS Shares Acquired by Capital World Investors - MarketBeat
NewAmsterdam Pharma Company N.V. $NAMS Shares Bought by American Century Companies Inc. - MarketBeat
Louis Lange Sells 28,186 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock - MarketBeat
NewAmsterdam Pharma (NASDAQ:NAMS) CEO Sells $14,753,257.75 in Stock - MarketBeat
Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) Insider Sells $3,165,350.10 in Stock - MarketBeat
Johannes Jacob Piete Kastelein Sells 101,409 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock - MarketBeat
(NAMS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Trend Report: Is NewAmsterdam Pharma Company NV Equity Warrant stock trending bullishMarket Performance Summary & Daily Technical Forecast Reports - baoquankhu1.vn
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Stock Recap: Is NewAmsterdam Pharma Company NV Equity Warrant stock trending bullish2025 Technical Patterns & Smart Money Movement Tracker - baoquankhu1.vn
Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) CEO Sells $14,753,257.75 in Stock - Defense World
NewAmsterdam Pharma Hits Day Low at $30.20 Amid Price Pressure - Markets Mojo
NewAmsterdam Pharma (NAMS) Stock Analysis: Exploring a 46.68% Potential Upside Amidst Strong Buy Ratings - DirectorsTalk Interviews
NewAmsterdam Pharma CEO Sells Over $14 Million in Shares - TradingView
NewAmsterdam Pharma (NAMS) CEO sells 443,707 shares after option exercise - Stock Titan
NewAmsterdam Pharma (NASDAQ: NAMS) files Form 144 to sell 443,707 shares - Stock Titan
NewAmsterdam Pharma (NASDAQ:NAMS) Sees Large Volume IncreaseStill a Buy? - MarketBeat
NewAmsterdam Highlights Obicetrapib Progress in Investor Presentation - TipRanks
NewAmsterdam posts updated investor presentation highlighting obicetrapib efficacy, safety, IP and cash runway - TradingView
Obicetrapib data and AD signals in NewAmsterdam (NAMS) deck - Stock Titan
Handelsbanken Fonder AB Boosts Stake in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March - Sahm
JPMorgan Chase & Co. Has $37.04 Million Position in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) CEO Sells 58,253 Shares of Stock - MarketBeat
NewAmsterdam Pharma (NAMS) CEO exercises options and sells 306,293 shares - Stock Titan
Liquidity Mapping Around (NAMS) Price Events - Stock Traders Daily
Michael Davidson Sells 183,332 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock - MarketBeat
Rate Hike: Is NewAmsterdam Pharma Company NV stock overvalued or fairly pricedJuly 2025 Intraday Action & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
NAMS Stock Price and Chart — NASDAQ:NAMS - TradingView
NewAmsterdam Pharma (NAMS) Stock Analysis: A Biotech Play with 34.71% Upside Potential - DirectorsTalk Interviews
Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) Insider Sells 45,481 Shares of Stock - MarketBeat
NewAmsterdam Pharma CSO Sells Shares - TradingView
NewAmsterdam Pharma (NAMS) CSO executes 45,481-share stock sale - Stock Titan
[144] NewAmsterdam Pharma Co N.V. SEC Filing - Stock Titan
The Bull Case For NewAmsterdam Pharma (NAMS) Could Change Following Obicetrapib-Focused 2025 Results And Share Shelf Filing - simplywall.st
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
NAMS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Q1 Earnings Forecast for NAMS Issued By HC Wainwright - MarketBeat
Published on: 2026-02-22 03:05:00 - baoquankhu1.vn
Can NewAmsterdam Pharma Company N.V. Equity Warrant stock beat analyst upgradesGap Up & Reliable Volume Spike Alerts - mfd.ru
What is HC Wainwright's Estimate for NAMS Q3 Earnings? - MarketBeat
6,000‑Share Rule 144 Sale by NewAmsterdam Pharma (NASDAQ: NAMS) - Stock Titan
Cantor Fitzgerald Maintains Overweight on NAMS NewAmsterdam Pharma Feb 2026 - Meyka
Cantor Fitzgerald reiterates NewAmsterdam Pharma stock rating at Overweight - Investing.com Nigeria
Guggenheim raises NewAmsterdam Pharma stock price target on EU launch timing - Investing.com Nigeria
Cantor Fitzgerald reiterates NewAmsterdam Pharma stock rating at Overweight By Investing.com - Investing.com Australia
Readystate Asset Management LP Sells 196,841 Shares of NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
Ideas Watch: What are NewAmsterdam Pharma Company NVs technical support levels2025 Growth vs Value & Step-by-Step Swing Trade Plans - baoquankhu1.vn
Aberdeen Group plc Has $18.83 Million Stock Holdings in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
Needham & Company LLC Issues Positive Forecast for NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price - Defense World
Finanzdaten der Newamsterdam Pharma Company Nv-Aktie (NAMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.18%
0.28%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):